Clinical Trial Update: Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients [Phase 3]

View source ↗

Summary

Phase 3 study evaluating Gadavist (gadobutrol) as an MRI contrast agent for brain or spine diseases in Chinese patients; the trial has completed and results wer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Diseases

Drugs mentioned

• Gadavist (gadobutrol)

Snippet

Sponsor: Bayer | Conditions: Central Nervous System Diseases | Phase 3 | Status: COMPLETED | Results posted: 2011-11-01